ASCO 2024 | Immunotherapy for recurrent respiratory papillomatosis (RRP) using PRGN-2012
Scott Norgberg, DO, National Cancer Institute, Bethesda, MD, discusses the application of immunotherapy to treat recurrent respiratory papillomatosis (RRP) by selectively targeting human papillomavirus types 6 (HPV 6) and 11 (HPV 11), reducing the need for repeat surgical debulking. Utilising the gorilla adenoviral vector PRGN-2012 to deliver DNA encoding HPV 6 and HPV 11 antigens, the immune system’s T-cell response against these virus types is enhanced. In Phase I/II trials (NCT04724980), four doses of PRGN-2012 were administered over three months post-surgery to assess safety, the need for further surgeries, and to determine if additional repeat treatments are necessary through a confirmatory study. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Patents, Royalties, Other Intellectual Property – I have patents or patents pending related to cell therapy and liquid biopsy technologies.
